These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1456195)

  • 1. Combining insulin and oral agents in diabetes: indications and controversies.
    Rosenthal TC
    Am Fam Physician; 1992 Dec; 46(6):1721-7. PubMed ID: 1456195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination insulin-sulfonylurea therapy in type II diabetes mellitus.
    Allen BT; Feinglos MN
    South Med J; 1987 Oct; 80(10):1285-9. PubMed ID: 3310252
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic management of the secondary failure of sulfonylurea therapy].
    Sauer H
    Dtsch Med Wochenschr; 1985 Jan; 110(1):27-30. PubMed ID: 3880697
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hypoglycemia: danger to life of diabetic patients. Higher price for blood sugar adjustment].
    Füessl HS
    MMW Fortschr Med; 2005 Aug; 147(31-32):4-6, 8. PubMed ID: 16128187
    [No Abstract]   [Full Text] [Related]  

  • 5. Are oral hypoglycemic agents likely to benefit NIDDM patients? Affirmative.
    Lebovitz HE
    Hosp Pract (Off Ed); 1992 Feb; 27 Suppl 1():26-31; discussion 35-6. PubMed ID: 1347536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus.
    Riddle MC
    Diabetes Res Clin Pract; 1991 Jan; 11(1):3-8. PubMed ID: 2019232
    [No Abstract]   [Full Text] [Related]  

  • 7. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea.
    Dworacka M; Abramczyk M; Winiarska H; Kuczynski S; Borowska M; Szczawinska K
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):14-21. PubMed ID: 16425966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
    Quatraro A; Consoli G; Ceriello A; Giugliano D
    Diabete Metab; 1986 Dec; 12(6):315-8. PubMed ID: 3545931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination use of sulfonylureas and insulin in the treatment of noninsulin-dependent diabetes mellitus.
    Montgomery PA
    Pharmacotherapy; 1992; 12(4):292-9. PubMed ID: 1518728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
    Simons WR; Hagan MA
    Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
    Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
    Bell DS; Ovalle F
    Endocr Pract; 2000; 6(4):293-5. PubMed ID: 11242605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 18. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude.
    Wallace TM; Matthews DR
    QJM; 2000 Jun; 93(6):369-74. PubMed ID: 10873187
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of two sulfonylureas. Does it make sense.
    Salo S; Groop L
    Diabetes Care; 1988 Oct; 11(9):751-3. PubMed ID: 3147175
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
    Simpson HC; Sturley R; Stirling CA; Reckless JP
    Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.